Compare ELWT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELWT | BOLD |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 54.5M |
| IPO Year | 2025 | 2024 |
| Metric | ELWT | BOLD |
|---|---|---|
| Price | $3.05 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.2K | ★ 86.2K |
| Earning Date | 11-16-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.37 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,618,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $111.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.48 | N/A |
| 52 Week Low | $2.70 | $0.96 |
| 52 Week High | $9.72 | $3.16 |
| Indicator | ELWT | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 20.92 | 42.40 |
| Support Level | N/A | $2.32 |
| Resistance Level | $7.99 | $2.65 |
| Average True Range (ATR) | 0.50 | 0.10 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 8.53 | 9.52 |
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.